<DOC>
	<DOCNO>NCT02617927</DOCNO>
	<brief_summary>The safety assessment Vedolizumab pregnancy IBD patient . The primary objective study : 1 . To quantify incidence major structural birth defect birth outcome infant born woman UC/CD exposure Entyvio compare woman exposure biological agent conventional IBD therapy pregnancy 2 . To assess health developmental status infant 1yr age .</brief_summary>
	<brief_title>The Safety Assessment Vedolizumab During Pregnancy IBD Patient</brief_title>
	<detailed_description>The IBD MOM clinic currently follow woman IBD preconception stage postpartum period . In addition , start follow offspring 1 year option extend follow 4 year birth participation family health center . Data collect longitudinally use non-immunomodulator medication , AZA/6MP , biologic therapy infliximab , adalimumab , certolizumab , natalizumab . Corticosteroids,5-ASA Methotrexate ) , disease activity gestation , complication pregnancy delivery , infant birth outcome first year child 's life population-based data , include Kaiser sample1 study Europe2-4 woman IBD clearly increase risk adverse pregnancy outcome preterm birth and/or low birth weight infant , even inactive disease.10 . Study duration : September 2015- September 2022 This non-interventional observational prospective cohort study conduct actual clinical practice set . This exposure-based cohort study 3 reference group . Women conventional therapy , woman Vedolizumab woman biologics . The source database contain information collect IBD MOM clinic Shaare Zedek Medical Center Jerusalem , Israel .</detailed_description>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Inclusion Criteria UC/CD Prospective Cohort : The subject currently pregnant woman UC CD The subject exposure Entyvio biologic agent conventional therapy ( nonbiological therapy ) dose , time first day LMP , The subject enroll later 19 complete week LMP . All pregnancy Entyvio user include study . Those recruit prior Week 20 enter prospective registry , recruit week 20 ( include retrospective report delivery ) enter separate Case Series . The subject agree condition requirement study include interview schedule , release medical record , physical examination live bear infant . Exclusion Criteria UC/CD Prospective Cohort : The subject &gt; 19 complete week gestation prior enrollment , The subject first contact OTIS prenatal diagnosis major structural defect , The subject enrol registry previous pregnancy , The subject exposure know suspected human teratogen : Chlorambucil Cyclophosphamide Mycophenylate mofetil Any Entyvio expose mother meet entry criterion enter Entyvio case series , use provide support data cohort study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>